Contrasting Aprea Therapeutics (NASDAQ:APRE) and Oncobiologics (NASDAQ:OTLK)

Aprea Therapeutics (NASDAQ:APRE) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Earnings & Valuation

This table compares Aprea Therapeutics and Oncobiologics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290,000.00	26.05	-$12.60 million	($1.08)	-0.56
Oncobiologics	$1.35 million	101.67	-$62.42 million	($0.77)	-0.73

Aprea Therapeutics has higher earnings, but lower revenue than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Aprea Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Aprea Therapeutics and Oncobiologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1	1	3	0	2.40
Oncobiologics	1	2	2	0	2.20

Aprea Therapeutics currently has a consensus target price of $3.07, suggesting a potential upside of 411.11%. Oncobiologics has a consensus target price of $5.20, suggesting a potential upside of 822.31%. Given Oncobiologics’ higher probable upside, analysts plainly believe Oncobiologics is more favorable than Aprea Therapeutics.

Insider and Institutional Ownership

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by insiders. Comparatively, 1.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Aprea Therapeutics and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	N/A	-47.60%	-40.97%
Oncobiologics	N/A	N/A	-254.82%

Summary

Aprea Therapeutics beats Oncobiologics on 8 of the 13 factors compared between the two stocks.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.